Article ; Online: Endovascular thrombectomy and intravenous alteplase in patients with acute ischemic stroke due to large vessel occlusion: A clinical practice guideline.
Journal of evidence-based medicine
2022 Volume 15, Issue 3, Page(s) 263–271
Abstract: Aim: Whether or not use of intravenous alteplase in combination with endovascular thrombectomy (EVT) improves outcomes versus EVT alone, for acute stroke patients with large vessel occlusion presenting directly to a comprehensive stroke center, is ... ...
| Abstract | Aim: Whether or not use of intravenous alteplase in combination with endovascular thrombectomy (EVT) improves outcomes versus EVT alone, for acute stroke patients with large vessel occlusion presenting directly to a comprehensive stroke center, is uncertain. Methods: Six randomized trials exploring this issue were published, and we synthesized this evidence to inform a rapid guideline based on the Guidelines International Network principles and guided by the GRADE approach. Results: We enlisted an international panel that included 4 patient partners and 1 caregiver, individuals from 6 countries. The panel considered low certainty evidence that EVT alone, relative to EVT with intravenous alteplase, possibly results in a small decrease in the proportion of patients that achieve functional independence and possibly a small increase in mortality. Both effect estimates were downgraded twice due to very serious imprecision. The panel also considered moderate certainty evidence that EVT alone probably decreases symptomatic intracranial hemorrhage, versus EVT with alteplase, and combination therapy was more costly than EVT alone. As a result of the low certainty for improved recovery without impairment and mortality for combination therapy versus EVT alone, and moderate certainty for increased harm with combination therapy, the panel made a weak recommendation in favor of EVT alone for stroke patients eligible for both treatments, and initially presenting directly to a comprehensive stroke center that provides both treatments. Conclusions: Consistent with this weak recommendation, optimal patient management will likely often include co-treatment with intravenous alteplase, depending on local circumstances and patient presentation. |
|---|---|
| MeSH term(s) | Brain Ischemia/drug therapy ; Brain Ischemia/therapy ; Endovascular Procedures/methods ; Fibrinolytic Agents/therapeutic use ; Humans ; Ischemic Stroke ; Stroke/therapy ; Thrombectomy/methods ; Thrombolytic Therapy/methods ; Tissue Plasminogen Activator/therapeutic use ; Treatment Outcome |
| Chemical Substances | Fibrinolytic Agents ; Tissue Plasminogen Activator (EC 3.4.21.68) |
| Language | English |
| Publishing date | 2022-09-19 |
| Publishing country | England |
| Document type | Journal Article |
| ZDB-ID | 2474496-7 |
| ISSN | 1756-5391 ; 1756-5383 |
| ISSN (online) | 1756-5391 |
| ISSN | 1756-5383 |
| DOI | 10.1111/jebm.12493 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.